heart disease
Conditions
Interventions
Experimental group:Qi-Li Qiang-Xin capsule + Low-salt and low-fat diet, anti-platelet aggregation, diuretics, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor antagon
Control group:Low-salt and low-fat diet, anti-platelet aggregation, diuretics, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists, lipid-lowering drugs stat
Sponsors
China-Japan Union Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
28 Years to 86 Years
Inclusion criteria
Inclusion criteria: The patients with the following symptoms were included: left ventricular end-diastolic diameter (LVEDd) > 5.0 cm (female), LVEDd > 5.5 cm (male); left ventricular ejection fraction (LVEF) < 45 %, and/or left ventricular shortening rate (LVFS) <25%; NYHA functional classification from I to IV.
Exclusion criteria
Exclusion criteria: HF due to severe valvular heart disease or hypertrophic cardiomyopathy; severe liver and kidney dysfunction, autoimmune disease, infectious disease, myocarditis, tumor or acute left heart failure; taking non-steroidal anti-inflammatory drugs, steroid hormones and immunological preparations; having contraindications for the use of sputum capsules; Myocarditis caused by alcoholic cardiomyopathy, anemia heart disease, ischemic cardiomyopathy, hypertension, coronary heart disease, etc.; acute pulmonary edema, cardiogenic shock, fatal arrhythmia, acute myocardial infarction; pregnant or lactating women; severe liver and kidney dysfunction, malignant tumors, and mental patients; and taking other traditional Chinese medicine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Minnesota Living with Heart Failure Questionnaire (MLHFQ) score; | — |
Countries
China
Contacts
Public ContactLiu Long
China-Japan Union Hospital of Jilin University
Outcome results
None listed